用于非酒精性脂肪性肝炎治疗的THR-β激动剂：一种有前景药物面临的挑战 - Suppr

Suppr

超能文献

THR-β Agonist for Nonalcoholic Steatohepatitis Treatment: Challenges of a Promising Drug.

作者信息

Xue Feng, Wei Lai

机构信息

School of Clinical Medicine, Tsinghua University, Beijing, China.

Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.

出版信息

J Clin Transl Hepatol. 2024 Aug 28;12(8):755-757. doi: 10.14218/JCTH.2024.00100. Epub 2024 Jun 20.

DOI:10.14218/JCTH.2024.00100

PMID:39130621

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11310755/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9863/11310755/c3d0a2361d24/JCTH-12-755-g001.jpg

相似文献

THR-β Agonist for Nonalcoholic Steatohepatitis Treatment: Challenges of a Promising Drug.用于非酒精性脂肪性肝炎治疗的THR-β激动剂：一种有前景药物面临的挑战

J Clin Transl Hepatol. 2024 Aug 28;12(8):755-757. doi: 10.14218/JCTH.2024.00100. Epub 2024 Jun 20.

Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.瑞美替隆：一种口服的小分子、肝脏靶向、β 选择性甲状腺激素受体激动剂，用于治疗非酒精性脂肪性肝病和非酒精性脂肪性肝炎。

touchREV Endocrinol. 2023 May;19(1):60-70. doi: 10.17925/EE.2023.19.1.60. Epub 2023 May 1.

Discovery of Highly Potent and Selective Thyroid Hormone Receptor β Agonists for the Treatment of Nonalcoholic Steatohepatitis.发现用于治疗非酒精性脂肪性肝炎的高效且选择性的甲状腺激素受体β激动剂。

J Med Chem. 2023 Mar 9;66(5):3284-3300. doi: 10.1021/acs.jmedchem.2c01669. Epub 2023 Feb 17.

Resmetirom瑞司美托

Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges.肝移植治疗非酒精性脂肪性肝炎：复发的病理生理学和临床挑战。

Dig Dis Sci. 2019 Dec;64(12):3413-3430. doi: 10.1007/s10620-019-05716-1. Epub 2019 Jul 16.

Inhibition of plasminogen suppresses fibrosis and macrophage foaming in a nonalcoholic steatohepatitis mouse model.纤溶酶原抑制可抑制非酒精性脂肪性肝炎小鼠模型的纤维化和巨噬细胞泡沫化。

Fundam Clin Pharmacol. 2022 Oct;36(5):827-836. doi: 10.1111/fcp.12774. Epub 2022 Mar 13.

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.双重过氧化物酶体增殖物激活受体α/δ激动剂 GFT505 在非酒精性脂肪性肝病/非酒精性脂肪性肝炎啮齿动物模型中的保肝作用。

Hepatology. 2013 Dec;58(6):1941-52. doi: 10.1002/hep.26461. Epub 2013 Oct 29.

Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir.非酒精性脂肪性肝炎对阿德福韦肾滤过及分泌的影响。

Biochem Pharmacol. 2016 Sep 1;115:144-51. doi: 10.1016/j.bcp.2016.07.001. Epub 2016 Jul 2.

Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status.奥贝胆酸治疗非酒精性脂肪性肝炎：现状

Euroasian J Hepatogastroenterol. 2022 Jul;12(Suppl 1):S46-S50. doi: 10.5005/jp-journals-10018-1360.

A Single-Center Study of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Recurrence in Recipients of Liver Transplant for Treatment of Nonalcoholic Steatohepatitis Cirrhosis.一项关于非酒精性脂肪性肝病和非酒精性脂肪性肝炎在接受肝移植治疗非酒精性脂肪性肝炎肝硬化患者中的复发的单中心研究。

Exp Clin Transplant. 2022 Feb;20(2):150-156. doi: 10.6002/ect.2021.0343. Epub 2022 Jan 14.

本文引用的文献

The first MASH drug therapy on the horizon: Current perspectives of resmetirom.地平线上的首个 MASH 药物治疗：雷美替胺的当前观点。

Liver Int. 2024 Jul;44(7):1526-1536. doi: 10.1111/liv.15930. Epub 2024 Apr 5.

Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease.振动控制瞬时弹性成像评分预测脂肪性肝病患者的肝脏相关事件。

JAMA. 2024 Apr 16;331(15):1287-1297. doi: 10.1001/jama.2024.1447.

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。

N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.雷美替胺治疗非酒精性脂肪性肝病：一项随机、双盲、安慰剂对照的 3 期临床试验。

Nat Med. 2023 Nov;29(11):2919-2928. doi: 10.1038/s41591-023-02603-1. Epub 2023 Oct 16.

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.美国肝病研究学会非酒精性脂肪性肝病临床评估与管理实践指南

Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.

Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia.瑞司美托（MGL-3196）用于杂合子家族性高胆固醇血症患者。

J Am Coll Cardiol. 2022 Mar 29;79(12):1220-1222. doi: 10.1016/j.jacc.2022.01.023.

Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease.非酒精性脂肪性肝病药物治疗的成本效益和潜在价值。

J Med Econ. 2022 Jan-Dec;25(1):347-355. doi: 10.1080/13696998.2022.2026702.

2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis.2019 年全球非酒精性脂肪性肝病患病率：系统评价和荟萃分析。

Clin Gastroenterol Hepatol. 2022 Dec;20(12):2809-2817.e28. doi: 10.1016/j.cgh.2021.12.002. Epub 2021 Dec 7.

Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.经活检证实的非酒精性脂肪性肝病的死亡率：一项全国性队列研究的结果。

Gut. 2021 Jul;70(7):1375-1382. doi: 10.1136/gutjnl-2020-322786. Epub 2020 Oct 9.

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.Resmetirom（MGL-3196）治疗非酒精性脂肪性肝炎：一项多中心、随机、双盲、安慰剂对照的 2 期临床试验。

Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6. Epub 2019 Nov 11.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验